(2-Bromo-3-fluoropyridin-4-yl)boronic acid, 97%, 1g

3-Iodo-4-methyl-1H-indazole, 95.0%, 1g

3,3',5,5'-TETRAMETHYL-BIPHENYL-2,2',6,6'-TETRAOL, 95.0%, 1g

2-Bromocyclohexanone, 98.0%, 5g

4-(3-Methoxyphenoxy)benzaldehyde, 97%, 250mg

3-Trimethylsilyl-2-oxazolidinone [Trimethylsilylating Reagent]>97.0%(GC)5g

1-Isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide, 98%, 250mg

Plan phase PLPHi S100x/1.25 oil immersion infinity corrected IOS objective. Working distance 0.36 mm

1-(2-Pyridinyl)-2-propanol, 95.0%, 250mg

(S)-2-Amino-3-(4-hydroxyphenyl)propanamide, 95.0%, 25g

(2,4-Dichlorophenyl)(phenyl)methanone, 95.0%, 1g

2-Pyrazinemethanol>98.0%(GC)1g

4-Iodo-3-methylphenol, 97.0%, 100g